Stock Mumak

Stock Profile

Revolution Medicines

Revolution Medicines is one of the most exciting biotech stocks for 2026. Strong Phase 3 data and a leading RAS oncology pipeline open up significant growth potential.

Stock Snapshot

Table HeaderTable Header
CompanyRevolution Medicines, Inc.
SectorHealthcare
ThemeBiotechnology / Precision Oncology
Business ModelDevelopment of targeted therapies for RAS-driven cancers
ISINUS76155X1000
Market Capitalizationapprox. $32.7 billion USD
UMBRELLA StatusActive

Mumak Score Card

Geopolitics

Industry

Fundamentals

Sentiment

Technical Analysis

Price Performance (12 Months)

Posts on Revolution Medicines

Revolution Medicines
Healthcare

Valuation Analysis: Revolution Medicines

ISIN: US76155X1000

Revolution Medicines is among the most compelling biotech companies in 2026. Positive Phase 3 data, a strong pipeline, and high
Active icon
More research

Latest Portfolio Updates

Weekly Update

Weekly Market Overview – June 8-14, 2026

AI and healthcare innovation are shaping the markets. The UMBRELLA Strategy increases its focus on quality companies and reduces cyclical
Next Update
Weekly Update

Weekly Market Overview – June 1-7, 2026

The UMBRELLA strategy has completed its portfolio restructuring, further strengthening its focus on Artificial Intelligence, cloud infrastructure, and data analysis.
Next Update
Weekly Update

Weekly Market Overview – May 25–31, 2026

The UMBRELLA Strategy is placing a stronger emphasis on AI, technology, healthcare, and defense. Tesla remains the largest single position.
Next Update
Weekly Update

Weekly Market Overview – May 18-24, 2026

Tech strength supports markets, but robust US data fuels renewed interest rate concerns and weighs on renewable energy. Learn everything
Next Update